A study has found that cannabis can reduce spasticity in multiple sclerosis patients. A systematic review found that five out six randomized controlled trials reported a reduction in spasticity and an improvement in mobility in multiple sclerosis patients.
Researchers searched electronic databases for relevant studies using randomized controlled trials evaluating the cannabis extracts delta9-tetrahydrocannabinol (THC) and cannabidiol (CBD). According to the researchers, “We found evidence that combined THC and CBD extracts may provide therapeutic benefit for multiple sclerosis spasticity symptoms”.
Spasticity, involuntary muscle tension or contraction, is a common symptom of multiple sclerosis. Many existing therapies for this symptom are ineffective, difficult to obtain, or associated with intolerable side effects. In this study, reported incidence of side effects from cannabis, such as intoxication, varied greatly depending on the amount of cannabis needed to effectively limit spasticity, but the researchers note that side effects were also seen in the placebo groups. They add, “Considering the distress and limitations spasticity brings to individuals with multiple sclerosis, it is important to carefully weigh the potential for side effects with the potential for symptom relief “.
Study author Shaheen Lakhan concludes, “The therapeutic potential of cannabinoids in multiple sclerosis is comprehensive and should be given considerable attention”.
References:
1. Shaheen E Lakhan, et al. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurology 2009, 9:59. doi:10.1186/1471-2377-9-59.
